SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Knoll Capital Management, LLC

CIK 0001325083 · 201 S. BISCAYNE BLVD, SUITE 800, MIAMI, FL, 33131 · 212-808-7474

Reported Value
$122M
Q2 2019
Positions
22
Filings on Record
30
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Knoll Capital Management, LLC reported $122M in U.S.-listed holdings across 22 positions for Q2 2019.

The portfolio is heavily concentrated: CRBPEUR alone accounts for 28.3% of reported value.

Compared with Q1 2019, the fund opened 6 new positions and exited 1.

Portfolio Metrics

Turnover
+10.6%
vs prior filed quarter
Top-10 Concentration
+89.5%
share of reported value
Largest Position
+28.3%
Corbus Pharmaceuticals
New / Exited
6 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $88MQ4 ’18Q1 ’19: $132MQ2 ’19: $122MQ3 ’19: $109MQ4 ’19: $135MQ4 ’19Q1 ’20: $106MQ2 ’20: $173MQ3 ’20: $122MQ4 ’20: $147MQ4 ’20Q2 ’21: $191MQ3 ’21: $201MQ4 ’21: $182MQ1 ’22: $159MQ1 ’22Q2 ’22: $175MQ3 ’22: $171MQ4 ’22: $44MQ1 ’23: $65MQ1 ’23Q2 ’23: $82MQ3 ’23: $96MQ4 ’23: $121MQ1 ’24: $161MQ1 ’24Q2 ’24: $148MQ3 ’24: $216MQ4 ’24: $155MQ1 ’25: $154MQ1 ’25Q2 ’25: $141MQ3 ’25: $187MQ4 ’25: $218MQ1 ’26: $180MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 66.6%Other: 30.9%ETP: 2.4%
  • Common Stock · 66.6% · $81M
  • Other · 30.9% · $38M
  • ETP · 2.4% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
APLTApplied Therapeutics IncNEW+467.1K467.1K+$4M$4M
DWDPEURDupont de Nemours IncNEW+30.0K30.0K+$2M$2M
DOWDow IncNEW+30.0K30.0K+$1M$1M
CTVACorteva IncNEW+30.0K30.0K+$887,000$887,000
Catasys IncNEW+14.6K14.6K+$281,000$281,000
Vascular Biogenics LtdNEW+21.4K21.4K+$28,000$28,000
CLDNEUREiger Biopharmaceuticals IncADDED+275.0K350.2K+$3M$4M
DowDupont IncSOLD OUT−90.0K0−$5M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

22 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CRBPEURCorbus Pharmaceuticals HLDGShistory →COM28.29%$35M4.99M
2Biohaven Pharmactl Hldg Co LCOM26.88%$33M749.8K
3ABEO1EURAbeona Therapeutics Inchistory →COM9.23%$11M2.36M
4BXUSDBlackstone Group LPhistory →COM UNIT LTD5.56%$7M153.0K
5KRYSKrystal Biotech Inchistory →COM4.85%$6M147.1K
6MOAltria Group Inchistory →COM3.49%$4M90.0K
7APLTApplied Therapeutics Inchistory →COM3.15%$4M467.1K
8CLDNEUREiger Biopharmaceuticals Inchistory →COM3.04%$4M350.2K
9ALDXAldeyra Therapeutics Inchistory →COM2.60%$3M529.4K
10Kraneshares TRBOSERA MSCI CH2.43%$3M96.0K
11AVXLAnavex Life Sciences Corphistory →COM NEW2.00%$2M724.2K
12DWDPEURDupont de Nemours Inchistory →COM1.84%$2M30.0K
13Galmed Pharmaceuticals LtdSHS1.24%$2M206.1K
14DOWDow Inchistory →COM1.21%$1M30.0K
15Entera Bio LtdSHS1.21%$1M475.5K
16Molecular TemplatesCOM0.78%$951,000113.9K
17CTVACorteva IncCOM0.73%$887,00030.0K
18ECORGBPElectrocore IncCOM0.65%$794,000396.8K
19Soligenix Inc.COM0.49%$595,000837.8K
20Catasys IncCOM PAR0.23%$281,00014.6K
21Lipocine Inc NewCOM0.08%$97,00050.0K
22Vascular Biogenics LtdCOM0.02%$28,00021.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$180M37May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$218M34Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$187M39Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$141M38Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$154M36May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$155M35Feb 18, 202513F-HRchanges · EDGAR ↗
Q3 2024$216M36Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$148M35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$161M34May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M32Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$96M37Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$82M27Aug 15, 202313F-HRchanges · EDGAR ↗
Q1 2023$65M26May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$44M21Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$171M33Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$175M41Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$159M41May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$182M38Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$201M40Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$191M42Aug 16, 202113F-HRchanges · EDGAR ↗
Q4 2020$147M31Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$122M30Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$173M19Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$106M18May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$135M18Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$109M23Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$122M22Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$132M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$88M15Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.